Activity of blinatumomab in lymphoblastic leukemia with impaired T-cell immunity due to congenital immunodeficiency

Blinatumomab, a single-chain, bispecific, T-cell–engaging antibody targeting CD19, is effective in B-precursor acute lymphoblastic leukemia (BCP-ALL), even in the context of chemotherapy-related partial T-cell immunodeficiency. We report 2 patients with BCP-ALL and congenital T-cell immunodeficiency...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood Adv
Hlavní autoři: Ramdeny, Sandheeah, Chaudhary, Asima, Worth, Austen, Ghorashian, Sara, Slatter, Mary, Lum, Su Han, Vora, Ajay
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2021
Témata:
Exceptional Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8095136/
https://ncbi.nlm.nih.gov/pubmed/33881461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2021004284
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky